Outcome of acute myeloid leukaemia following myelodysplastic syndrome after azacitidine treatment failure

被引：45

作者：

Prebet, Thomas ^{[1
,2
,3
]}

Gore, Steven D. ^{[1
,3
]}

Thepot, Sylvain ^{[3
]}

Esterni, Benjamin ^{[2
]}

Quesnel, Bruno ^{[3
]}

Rauzy, Odile Beyne ^{[3
]}

Dreyfus, Francois ^{[3
]}

Gardin, Claude ^{[3
]}

Fenaux, Pierre ^{[3
]}

Vey, Norbert ^{[2
,3
]}

机构：

[1] Johns Hopkins Univ, Sidney Kimmel Canc Ctr, Dept Hematol Malignancies, Baltimore, MD 21218 USA

[2] Inst J Paoli I Calmettes, Dept Hematol, F-13009 Marseille, France

[3] Grp Francophone Myelodysplasies, Bobigny, France

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2012年 / 157卷 / 06期

关键词：

Myelodysplasia; acute myeloid leukaemia; azacitidine; relapse; outcome; CONVENTIONAL CARE REGIMENS;

D O I：

10.1111/j.1365-2141.2012.09076.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：764 / 766

页数：3

共 10 条

[1] Outcomes After Induction Chemotherapy in Patients With Acute Myeloid Leukemia Arising From Myelodysplastic Syndrome [J].

Bello, Celeste ;

Yu, Daohai ;

Komrokji, Rami S. ;

Zhu, Weiwei ;

Wetzstein, Gene A. ;

List, Alan F. ;

Lancet, Jeffrey E. .

CANCER, 2011, 117 (07) :1463-1469

[2] Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia [J].

Cheson, BD ;

Bennett, JM ;

Kopecky, KJ ;

Büchner, T ;

Willman, CL ;

Estey, EH ;

Schiffer, CA ;

Döhner, H ;

Tallman, MS ;

Lister, TA ;

LoCocco, F ;

Willemze, R ;

Biondi, A ;

Hiddemann, W ;

Larson, RA ;

Löwenberg, B ;

Sanz, MA ;

Head, DR ;

Ohno, R ;

Bloomfield, CD .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (24) :4642-4649

[3] Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies [J].

Fandy, Tamer E. ;

Herman, James G. ;

Kerns, Patrick ;

Jiemjit, Anchalee ;

Sugar, Elizabeth A. ;

Choi, Si-Ho ;

Yang, Allen S. ;

Aucott, Timothy ;

Dauses, Tianna ;

Odchimar-Reissig, Rosalie ;

Licht, Jonathan ;

McConnell, Melanie J. ;

Nasrallah, Chris ;

Kim, Marianne K. H. ;

Zhang, Weijia ;

Sun, Yezou ;

Murgo, Anthony ;

Espinoza-Delgado, Igor ;

Oteiza, Katharine ;

Owoeye, Ibitayo ;

Silverman, Lewis R. ;

Gore, Steven D. ;

Carraway, Hetty E. .

BLOOD, 2009, 114 (13) :2764-2773

[4] Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia [J].

Fenaux, Pierre ;

Mufti, Ghulam J. ;

Hellstrom-Lindberg, Eva ;

Santini, Valeria ;

Gattermann, Norbert ;

Germing, Ulrich ;

Sanz, Guillermo ;

List, Alan F. ;

Gore, Steven ;

Seymour, John F. ;

Dombret, Herve ;

Backstrom, Jay ;

Zimmerman, Linda ;

McKenzie, David ;

Beach, C. L. ;

Silverman, Lewis R. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (04) :562-569

[5] Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study [J].

Fenaux, Pierre ;

Mufti, Ghulam J. ;

Hellstrom-Lindberg, Eva ;

Santini, Valeria ;

Finelli, Carlo ;

Giagounidis, Aristoteles ;

Schoch, Robert ;

Gattermann, Norbert ;

Sanz, Guillermo ;

List, Alan ;

Gore, Steven D. ;

Seymour, John F. ;

Bennett, John M. ;

Byrd, John ;

Backstrom, Jay ;

Zimmerman, Linda ;

McKenzie, David ;

Beach, C. L. ;

Silverman, Lewis R. .

LANCET ONCOLOGY, 2009, 10 (03) :223-232

[6] Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms [J].

Gore, SD ;

Baylin, S ;

Sugar, E ;

Carraway, H ;

Miller, CB ;

Carducci, M ;

Grever, M ;

Galm, O ;

Dauses, T ;

Karp, JE ;

Rudek, MA ;

Zhao, M ;

Smith, BD ;

Manning, J ;

Jiemjit, A ;

Dover, G ;

Mays, A ;

Zwiebel, J ;

Murgo, A ;

Weng, LJ ;

Herman, JG .

CANCER RESEARCH, 2006, 66 (12) :6361-6369

[7] Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine [J].

Itzykson, Raphael ;

Thepot, Sylvain ;

Quesnel, Bruno ;

Dreyfus, Francois ;

Beyne-Rauzy, Odile ;

Turlure, Pascal ;

Vey, Norbert ;

Recher, Christian ;

Dartigeas, Caroline ;

Legros, Laurence ;

Delaunay, Jacques ;

Salanoubat, Celia ;

Visanica, Sorin ;

Stamatoullas, Aspasia ;

Isnard, Francoise ;

Marfaing-Koka, Anne ;

de Botton, Stephane ;

Chelghoum, Youcef ;

Taksin, Anne-Laure ;

Plantier, Isabelle ;

Ame, Shanti ;

Boehrer, Simone ;

Gardin, Claude ;

Beach, C. L. ;

Ades, Lionel ;

Fenaux, Pierre .

BLOOD, 2011, 117 (02) :403-411

[8] Aberrant DNA methylation is a dominant mechanism in MDS progression to AML [J].

Jiang, Ying ;

Dunbar, Andrew ;

Gondek, Lukasz P. ;

Mohan, Sanjay ;

Rataul, Manjot ;

O'Keefe, Christine ;

Sekeres, Mikkael ;

Saunthararajah, Yogen ;

Maciejewski, Jaroslaw P. .

BLOOD, 2009, 113 (06) :1315-1325

[9] Myelodysplastic syndromes [J].

Nimer, Stephen D. .

BLOOD, 2008, 111 (10) :4841-4851

[10] Outcome of High-Risk Myelodysplastic Syndrome After Azacitidine Treatment Failure [J].

Prebet, Thomas ;

Gore, Steven D. ;

Esterni, Benjamin ;

Gardin, Claude ;

Itzykson, Raphael ;

Thepot, Sylvain ;

Dreyfus, Francois ;

Rauzy, Odile Beyne ;

Recher, Christian ;

Ades, Lionel ;

Quesnel, Bruno ;

Beach, C. L. ;

Fenaux, Pierre ;

Vey, Norbert .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (24) :3322-3327

← 1 →